MCM2

DNA replication licensing factor MCM2 · P49736 · MCM2 on Sugi Atlas →

0 patent compounds predicted against MCM2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MCM2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease PHASE2COMPLETED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers PHASE1/PHASE2COMPLETED
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation PHASE2ACTIVE_NOT_RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma PHASE1/PHASE2RECRUITING
Clinical Study of Previously Untreated Patients With Malignant Melanoma PHASE2COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer PHASE1ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders PHASE1RECRUITING
Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia nanCOMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Microcephaly Genetic Deficiency in Neural Progenitors nanCOMPLETED
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. nanUNKNOWN
Study of Skin Cells That Stop Replicating (Senescent) During Wound Healing nanCOMPLETED
Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation nanUNKNOWN
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study nanCOMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING
Genetic Analysis of Familial Melanoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MCM2 binder may also engage these)

ProteinNameSimilarity
P55861 1.000 P55861 →
Q6DIH3 1.000 Q6DIH3 →
P97310 1.000 P97310 →
P49735 1.000 P49735 →
P34647 1.000 P34647 →
P29469 0.999 P29469 →
P97311 0.999 P97311 →
Q9LPD9 0.999 Q9LPD9 →
Q6P1V8 0.999 Q6P1V8 →
Q5ZMN2 0.998 Q5ZMN2 →
Q29JI9 0.998 Q29JI9 →
Q7ZY18 0.998 Q7ZY18 →
MCM3 DNA replication licensing factor MCM3 0.998 landscape →
Q7Q0Q1 0.998 Q7Q0Q1 →
P25206 0.997 P25206 →
Q5FWY4 0.997 Q5FWY4 →
Q9V461 0.997 Q9V461 →
A4FUD9 0.996 A4FUD9 →
B8BKI8 0.996 B8BKI8 →
Q498J7 0.996 Q498J7 →
Q9VF30 0.996 Q9VF30 →
Q9SX04 0.996 Q9SX04 →
Q61J08 0.995 Q61J08 →
P29458 0.995 P29458 →
Q7ZXB1 0.995 Q7ZXB1 →
P49731 0.995 P49731 →
Q0DHC4 0.995 Q0DHC4 →
Q7ZXZ0 0.995 Q7ZXZ0 →
Q95XQ8 0.995 Q95XQ8 →
Q5R8G6 0.995 Q5R8G6 →